First Tracks Q2 FY26 net loss narrows to $33.37 million

Reuters2026/08/12 20:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

First Tracks posted a Q2 net loss of $33.4 million, narrowing 21.36% from a $42.4 million loss a year earlier.
Loss per share improved to $0.95 from $1.47 in the prior-year quarter.
R&D expense fell 34.75% to $25.6 million, due to lower rosnilimab and ANB032 costs, partly offset by higher ANB033 spending.
G&A expense rose 40.26% to $9.3 million, due to legal costs tied to the separation.
Cash, cash equivalents and investments totaled $168 million; ANB033 celiac Cohort 1 data due Q4 2026, Cohort 2 due Q1 2027, EoE data due Q3 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. First Tracks Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121615PRIMZONEFULLFEED9808955) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

First Tracks Q2 FY26 net loss narrows to $33.37 million

You may also like

Crypto prices